Clinical Trials
65 trialsTazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
ELiPSE-1
Century Therapeutics, Inc.
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Regeneron Pharmaceuticals
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Roswell Park Cancer Institute
GLEAN-1
Adicet Therapeutics
Rituximab + Immunotherapy in Follicular Lymphoma
Dana-Farber Cancer Institute
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
TG Therapeutics, Inc.
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
University of California, San Francisco
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Amgen
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Ipilimumab and Local Radiation for Selected Solid Tumors
Stanford University
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Washington University School of Medicine
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
University of Washington
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
MEI Pharma, Inc.
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
AbbVie
Glio
Samus Therapeutics, Inc.
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
Eden BioCell Ltd.
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Swiss Cancer Institute
Study of LUCAR-20S in Patients With R/R NHL
The First Affiliated Hospital with Nanjing Medical University
Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19
Histogen
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
ADC Therapeutics S.A.
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Gilead Sciences
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Fred Hutchinson Cancer Center
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
Study of IV CBL0137 in Previously Treated Hematological Subjects
Incuron
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
Celgene
Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)
Merck Sharp & Dohme LLC
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
Janssen Research & Development, LLC
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
Seagen Inc.
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Wake Forest University Health Sciences
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Dartmouth-Hitchcock Medical Center
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
Masonic Cancer Center, University of Minnesota
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
UNC Lineberger Comprehensive Cancer Center
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
Duke University
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Alliance for Clinical Trials in Oncology
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
Duke University
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Case Comprehensive Cancer Center
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
Gilead Sciences
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
National Cancer Institute (NCI)